Belite Bio (BLTE) Net Income towards Common Stockholders (2022 - 2026)
Belite Bio (BLTE) posted quarterly Net Income towards Common Stockholders of -$0.68 for Q1 2026, down 251.11% year-over-year from $0.45 in Q1 2025, and down 197.14% quarter-over-quarter from $0.7 in Q4 2025.
Powered by 
Analysis
Belite Bio (BLTE) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Belite Bio's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$0.68 for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 251.11% year-over-year to -$0.68; the TTM figure through Mar 2026 stood at $1.17 (up 46.25% YoY), while the FY2025 annual figure was $2.31, up 95.76% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$0.68, down from $0.7 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $0.7 in Q4 2025, with the low at -$0.68 in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is $0.26 (2022), against an average of $0.14.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders plunged 300.0% in 2023, then soared 332.14% in 2025.
- Belite Bio's Net Income towards Common Stockholders stood at $0.27 in 2022, then retreated by 7.41% to $0.25 in 2023, then grew by 28.0% to $0.32 in 2024, then soared by 118.75% to $0.7 in 2025, then plunged by 197.14% to -$0.68 in 2026.
- Business Quant data shows BLTE's Net Income towards Common Stockholders at -$0.68 in Q1 2026, $0.7 in Q4 2025, and $0.65 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Belite Bio | 6.28 Bn | 6.28 Bn | - | -28.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.41 Mn |
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | -253.24 |
| Sep 30, 2025 | -21.69 Mn |
| Jun 30, 2025 | -16.32 Mn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | -101.00 |
| Sep 30, 2024 | -8.68 Mn |
| Jun 30, 2024 | -9.49 Mn |
| Mar 31, 2024 | -7.87 Mn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -68.12 |
| Mar 31, 2023 | -6.90 Mn |
| Dec 31, 2022 | -6.78 Mn |
| Jun 30, 2022 | -2.39 Mn |